|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
EIF2B3 DNA Sequencing
Test Code38391
CPT Codes
81406<br /> Restricted Client Code
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Preferred Specimen
8 mL whole blood collected in two EDTA (lavender-top) tubes
Pediatric (0-3 years): 2 mL
Pediatric (0-3 years): 2 mL
Minimum Volume
6 mL • Pediatric: 1 mL
Instructions
Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Note: Higher blood volumes ensure adequate DNA quantity, which varies with WBC, specimen condition, and need for confirmatory testing. Patients, 0-3 years may have higher WBC, yielding more DNA per mL of blood.
Note: Higher blood volumes ensure adequate DNA quantity, which varies with WBC, specimen condition, and need for confirmatory testing. Patients, 0-3 years may have higher WBC, yielding more DNA per mL of blood.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 10 days
Refrigerated: 10 days
Frozen: Unacceptable
Refrigerated: 10 days
Frozen: Unacceptable
Methodology
Sanger Sequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: As needed; Report Available: 14-28 days
Report Available
28 Days
Reference Range
No mutation detected
Clinical Significance
Detects mutations in the EIF2B3 gene
Typical Presentation: Age of onset ranges from a congenital form through an adult onset form. Neurologic symptoms include ataxia, spasticity and variable optic atrophy. Seizures may be a prominent feature in early onset forms.
Typical Presentation: Age of onset ranges from a congenital form through an adult onset form. Neurologic symptoms include ataxia, spasticity and variable optic atrophy. Seizures may be a prominent feature in early onset forms.
